Der Aldosteronantagonist Spironolakton hat seit seiner Einführung 1958 bis in die letzten Jahre eine bemerkenswerte, ständige Indikationserweiterung erfahren. Als wichtige Zielgruppe sind zuletzt Patienten mit resistenter, also schwer behandelbarer, Hypertonie hinzugekommen.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Roush GC, Ernst ME, J B Kostis et al. Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens. 2016;34:1–9
Dahal K, Kunwar S, J Rijal et al. The Effects of Aldosterone Antagonists in Patients With Resistant Hypertension: A Meta-Analysis of Randomized and Nonrandomized Studies. Am J Hypertens. 2015;28:1376–85
Vaclavik J, Sedlak R, J Jarkovskj et al. Effect of Spironolactone in Resistant Arterial Hypertension. A Randomized, Double-Blind, Placebo-Controlled Trial (ASPIRANT-EXT). Medicine. 2014;93:1–9
Verdalles U, de Vinusa SG, Goicoechea M et al. Management of resistant hypertension: Aldosterone antagonists or intensification of diuretic therapy? Nephrology. 2015;20:567–71
Williams B, MacDonald TM, S Morant et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Holzgreve, H. Erste Wahl bei resistenter Hypertonie. MMW - Fortschritte der Medizin 158, 65–70 (2016). https://doi.org/10.1007/s15006-016-8066-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15006-016-8066-7